Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight

The Lancet Psychiatry

Volumn 4, Issue 5, 2017, Pages 419-426

  Singh, Ilina ^a   Morgan, Celia ^b   Curran, Valerie ^c   Nutt, David ^d   Schlag, Anne ^e   McShane, Rupert ^f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; ANTIDEPRESSANT AGENT;

DISEASE SEVERITY; DRUG EFFICACY; DRUG MISUSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL ETHICS; OFF LABEL DRUG USE; PATIENT AUTONOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT RESISTANT DEPRESSION; DEPRESSION; ETHICS; LEGISLATION AND JURISPRUDENCE; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS; KETAMINE; OFF-LABEL USE; PATIENT SAFETY; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85017184333     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30102-5     Document Type: Review

References (69)

1. 1 Duman, RS, Aghajanian, GK, Neurobiology of rapid acting antidepressants: role of BDNF and GSK-3β. Neuropsychopharmacology, 39, 2014, 233.
2. 2 Zarate, CA Jr, Singh, JB, Carlson, PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63 (2006), 856–864.
3. 3 aan het Rot, M, Collins, KA, Murrough, JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67 (2010), 139–145.
4. 4 Machado-Vieira, R, Baumann, J, Wheeler-Castillo, C, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals 3 (2010), 19–41.
5. 5 Morgan, CJ, Curran, HV, Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction 107 (2012), 27–38.
6. 6 Taylor, P, Nutt, D, Curran, V, Fortson, R, Henderson, G, on behalf of DrugScience. Ketamine—the real perspective. Lancet 387 (2016), 1271–1272.
7. 7 Berman, RM, Cappiello, A, Anand, A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47 (2000), 351–354.
8. 8 Caddy, C, Amit, BH, McCloud, TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev, 9, 2015 CD011612.
9. 9 Price, RB, Nock, MK, Charney, DS, Mathew, SJ, Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66 (2009), 522–526.
10. 10 Wilkinson, ST, Sanacora, G, Ketamine: a potential rapid-acting antisuicidal agent?. Depress Anxiety 33 (2016), 711–717.
11. 11 Kerr, C, Holahan, T, Milch, R, The use of ketamine in severe cases of refractory pain syndromes in the palliative care setting: a case series. J Palliat Med 14 (2011), 1074–1077.
12. 12 Irwin, SA, Iglewicz, A, Nelesen, RA, et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med 16 (2013), 958–965.
13. 13 Anderson, IM, Blamire, A, Branton, T, et al., on behalf of the Ketamine-ECT Study team. Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. Lancet Psychiatry, 2017 published online March 27. http://dx.doi.org/10.1016/S2215-0366(17)30077-9.
14. 14 Morgan, CJ, Muetzelfeldt, L, Curran, HV, Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 105 (2010), 121–133.
15. 15 Shahani, R, Streutker, C, Dickson, B, Stewart, RJ, Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69 (2007), 810–812.
16. 16 Mason, K, Cottrell, AM, Corrigan, AG, Gillatt, DA, Mitchelmore, AE, Ketamine-associated lower urinary tract destruction: a new radiological challenge. Clin Radiol 65 (2010), 795–800.
17. 17 Gu, D, Huang, J, Yin, Y, Shan, Z, Zheng, S, Wu, P, Long-term ketamine abuse induces cystitis in rats by impairing the bladder epithelial barrier. Mol Biol Rep 41 (2014), 7313–7322.
18. 18 Cottrell, MA, Athreeres, R, Weinstock, P, Warren, K, Gillatt, D, Urinary tract disease associated with chronic ketamine use. BMJ, 336, 2008, 973.
19. 19 Gregoire, MC, MacLellan, DL, Finley, GA, A pediatric case of ketamine-associated cystitis (Letter-to-the-Editor Re. Shahani R, Streutker C, Dickson B, et al. Ketamine-associated ucerative cystitis: a new clinical entity). Urology 69 (2007), 810–812.
20. 20 Lapidus, KA, Levitch, CF, Perez, AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 76 (2014), 970–976.
21. 21 Radvansky, BM, Shah, K, Parikh, A, Sifonios, AN, Le, V, Eloy, JD, Role of ketamine in acute postoperative pain management: a narrative review. BioMed Res Int, 2015, 2015, 749837.
22. 22 Lahti, AC, Weiler, MA, Tamara Michaelidis, BA, Parwani, A, Tamminga, CA, Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25 (2001), 455–467.
23. 23 Perry, EB Jr, Cramer, JA, Cho, HS, et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) 192 (2007), 253–260.
24. 24 Zorumski, CF, Conway, CR, Use of ketamine in clinical practice: a time for optimism and caution. JAMA Psychiatry, 2017, 10.1001/jamapsychiatry.2017.0078 published online March 1.
25. 25 Malhi, GS, Lingford-Hughes, AR, Young, AH, Antidepressant treatment response: ‘I want it all, and I want it now!’. Br J Psychiatry 208 (2016), 101–103.
26. 26 Schak, KM, Vande Voort, JL, Johnson, EK, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry 173 (2016), 215–218.
27. 27 Sisti, D, Segal, AG, Thase, ME, Proceed with caution: off-label ketamine treatment for major depressive disorder. Curr Psychiatry Rep, 16, 2014, 527.
28. 28 Zhang, MW, Harris, KM, Ho, RC, Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications. BMC Med Ethics, 17, 2016, 4.
29. 29 Segal, A, Sisti, D, Research moratoria and off-label use of ketamine. Am J Bioeth 16 (2016), 60–61.
30. 30 Andreae, MH, Rhodes, E, Bourgoise, T, et al. An ethical exploration of barriers to research on controlled drugs. Am J Bioeth 16 (2016), 36–47.
31. 31 Schatzberg, AF, A word to the wise about ketamine. Am J Psychiatry 171 (2014), 262–264.
32. 32 Li, JH, Vicknasingam, B, Cheung, YW, et al. To use or not to use: an update on licit and illicit ketamine use. Subst Abuse Rehabil 2 (2011), 11–20.
33. 33 Zhang, MW, Ho, RC, Ethical considerations for clinical research and off-label use of ketamine to treat mood disorders: the balance between risks and benefits. Ethics Behav 9 (2016), 211–217.
34. 34 Loo, C, Is ketamine ready to be used clinically for the treatment of depression?. Med J Austr, 203, 2015, 425.
35. 35 Pescosolido, B, The public stigma of mental illness: What do we think; what do we know; what can we prove?. J Health Soc Behav 54 (2013), 1–21.
36. 36 Nuffield Council on Bioethics. Novel neurotechnologies: intervening in the brain, 2013, Nuffield Council on Bioethics, London.
37. 37 Corrigan, PW, Watson, AC, Barr, L, The self-stigma of mental illness: implications for self-esteem and self-efficacy. J Soc Clin Psychol 25 (2006), 875–884.
38. 38 Al-Harbi, KS, Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence 6 (2012), 369–388.
39. 39 Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163 (2006), 1905–1917.
40. 40 Hawton, K, Casañas, I, Comabella, C, et al. Risk factors for suicide in individuals with depression: a systematic review. J Affect Disord 147 (2013), 17–28.
41. 41 Cleare, A, Pariante, CM, Young, AH, et al., for Members of the Consensus Meeting. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 29 (2015), 459–525.
42. 42 Ionescu, DF, Swee, MB, Pavone, KJ, et al. Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. J Clin Psychiatry 77 (2016), 719–725.
43. 43 Conti, RM, Bernstein, AC, Villaflor, VM, et al. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol 31 (2013), 1134–1139.
44. 44 Sridharan, K, Arora, K, Chaudhary, S, Off-label drug use in psychiatry: a retrospective audit in a tertiary care hospital. Asian J Psychiatr, 24, 2016, 124.
45. 45 Wong, J, Motulsky, A, Eguale, T, Buckeridge, DL, Abrahamowicz, M, Tamblyn, R, Treatment indications for antidepressants prescribed in primary care in Quebec, Canada, 2006–2015. JAMA 315 (2016), 2230–2232.
46. 46 Cartwright, N, Are RCTs the gold standard?. BioSocieties 2 (2007), 11–20.
47. 47 Cartwright, N, A philosopher's view of the long road from RCTs to effectiveness. Lancet 377 (2011), 1400–1401.
48. 48 Schorck, N, Personalised medicine: time for one-person trials. Nature 520 (2015), 609–611.
49. 49 US Food and Drug Administration. Expanded access (compassionate use). http://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm (accessed Nov 10, 2016).
50. 50 Gillon, R, Ethics needs principles—four can encompass the rest—and respect for autonomy should be “first among equals”. J Med Ethics 29 (2003), 307–312.
51. 51 Frankfurt, H, The importance of what we care about, 1987, Cambridge University Press, Cambridge.
52. 52 Corrigan, O, Empty ethics: the problem with informed consent. Sociol Health Illn 25 (2003), 768–792.
53. 53 O'Neill, O, Symposium on consent and confidentiality: some limits of informed consent. J Med Ethics 29 (2003), 4–7.
54. 54 Gotlib, IH, Joorman, J, Cognition and depression: current status and future directions. Annu Rev Clin Psychol 6 (2010), 285–312.
55. 55 Di Schiena, R, Luminet, O, Chang, B, et al. Why are depressive individuals indecisive? Different modes of rumination account for indecision in non-clinical depression. Cognit Ther Res 37 (2013), 713–724.
56. 56 Pelto-Piri, V, Engström, K, Engström, I, Paternalism, autonomy and reciprocity: ethical perspectives in encounters with patients in psychiatric in-patient care. BMC Med Ethics, 14, 2013, 49.
57. 57 Schermer, M, Ethical issues in deep brain stimulation. Front Integr Neurosci, 5, 2011, 17.
58. 58 Niesters, M, Martini, C, Dahan, A, Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol 77 (2014), 357–367.
59. 59 Schoevers, RA, Chaves, TV, Balukova, SM, Rot, MA, Kortekaas, R, Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry 208 (2016), 108–113.
60. 60 Johnson & Johnson. Esketamine receives breakthrough therapy designation from US Food and Drug Administration for major depressive disorder with imminent risk for suicide. https://www.jnj.com/media-center/press-releases/esketamine-recieves-breakthrough-therapy-designation-from-us-food-and-drug-administration-for-major-depressive-disorder-with-imminent-risk-of-suicide (accessed Nov 10, 2016).
61. 61 van Leeuwen, E, Research on controlled drug use: a paradigm for public health research in sustainable health. Am J Bioeth 16 (2016), 50–52.
62. 62 Schoevers, RA, Chaves, TV, Balukova, SM, Rot, MA, Korekaas, R, Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry 208 (2016), 108–113.
63. 63 Jafarinia, M, Afarideh, M, Tafakhori, A, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial. J Affect Disord 204 (2016), 1–8.
64. 64 Mahesh, R, Sunilkumar, G, Preeth, S, Chandrasekhar, S, Therapy induced ketamine addiction. Case Study Case Rep 1 (2011), 146–149.
65. 65 Zanos, P, Moaddel, R, Morris, PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 (2016), 481–486.
66. 66 Leiderman, DB, Risk management of drug products and the U.S. Food and Drug Administration: evolution and context. Drug Alcohol Depend 105:suppl 1 (2009), S9–13.
67. 67 US Food and Drug Administration. Questions and answers on the federal register notice on drugs and biological products deemed to hve risk evaluation and mitigation strategies. http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/ucm095439.htm (accessed Nov 10, 2016).
68. 68 McCormick, CG, Henningfield, JE, Haddox, JD, et al. Case histories in pharmaceutical risk management. Drug Alcohol Depend 105:suppl 1 (2009), S42–S55.
69. 69 Sanacora, G, Frye, MA, McDonald, W, et al., for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 2017, 10.1001/jamapsychiatry.2017.0080 published online March 1.